Figure (Invega 01)
Invega Trinza Injection, Suspension, Extended Release
Product Images NDC 50458-609
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 30 technical images submitted to the FDA as part of the official labeling for Invega Trinza (NDC 50458-609). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Janssen Pharmaceuticals, Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure (Invega 02)
Figure (Invega 03)
An instructional illustration showing a syringe with labeled parts including syringe tip, rubber cap, luer connection, needle sheath, and needle pouch. It also depicts two types of needles: a 22 gauge by 1 inch needle with a pink tip and a 22 gauge by 1½ inch needle with a yellow tip.*
Figure (Invega 04)
An instructional illustration showing the outline of a human upper body with an arrow pointing to the deltoid muscle area of the shoulder, indicating the intramuscular injection site for the medication.*
Figure (Invega 05)
Illustration showing administration of an intramuscular injection into the upper arm area. The image highlights the injection site on the outer upper arm with an arrow pointing to the spot, demonstrating proper placement for an intramuscular injection.*
Figure (Invega 06)
A magenta label displaying white text "22G x 1 inch" indicating the size and gauge of a needle, typically used for intramuscular injections like INVEGA TRINZA by Janssen Pharmaceuticals.*
Figure (Invega 07)
A yellow label displaying the needle gauge and length for an injection: 22G x 1½ inch. The label provides size information relevant to the administration of an injectable drug, typically indicating the needle's thickness (22 gauge) and length (1.5 inches).*
Figure (Invega 08)
A close-up label panel showing needle size information: 22 gauge by 1 1/2 inches, typically used for injections such as the INVEGA TRINZA extended-release suspension injection by Janssen Pharmaceuticals.*
Figure (Invega 09)
The image shows a yellow label with black text indicating a needle size of 22 gauge and 1.5 inches in length (22G x 1 1/2"). This label is likely part of the packaging or instructions for the INVEGA TRINZA injection by Janssen Pharmaceuticals, Inc.*
Figure (Invega 10)
A medication instruction panel warning to immediately discard unused needles in an approved sharps container and advising not to save needles for future use.*
Figure (Invega 11)
Instructional panel for INVEGA TRINZA (paliperidone palmitate) extended-release intramuscular injection suspension. The label advises shaking the syringe vigorously for at least 15 seconds with the syringe tip pointing upward and a loose wrist to ensure a homogeneous suspension. It notes this medication requires more vigorous shaking than the 1-month formulation, and if more than 5 minutes elapse before injection, to shake again for at least 15 seconds before use.*
Figure (Invega 12)
An instructional illustration showing a hand holding a syringe with an extended-release suspension injection labeled INVEGA TRINZA (paliperidone palmitate). The illustration focuses on proper handling or preparation for intramuscular administration.*
Figure (Invega 13)
An instructional illustration showing how to use a device or product, divided diagonally into two frames: the upper left demonstrates opening or flipping a cover or lid with a hand, and the lower right shows removal of a component with an upward arrow and a rotational arrow indicating twisting action.*
Figure (Invega 14)
An instructional illustration showing a hand holding a syringe or vial, demonstrating the proper grip and technique for preparation or administration of an injection. The image likely relates to the use of INVEGA TRINZA, a paliperidone palmitate extended release intramuscular injection.*
Figure (Invega 15)
Illustration showing a hand holding a vial and using a small cloth or wipe to clean the vial cap with a swiping motion in a counterclockwise direction, likely demonstrating proper preparation technique for an injectable suspension.*
Figure (Invega 16)
Illustration showing a hand holding a syringe with a needle cap being pulled straight off in an upward direction, depicting a step in preparing an intramuscular injection for drug administration.*
Figure (Invega 17)
An instructional illustration showing two hands preparing an injection syringe. One hand holds the syringe, while the other hand pulls up the syringe plunger, indicated by an upward arrow. This image demonstrates the step for withdrawing or preparing the injection suspension, relevant to INVEGA TRINZA intramuscular extended-release injection.*
Figure (Invega 18)
Illustration showing injection sites for INVEGA TRINZA extended-release suspension. The diagram indicates the deltoid muscle or gluteal muscle as administration locations, highlighting the deltoid on the upper arm and the gluteal region on the buttocks for intramuscular injection.*
Figure (Invega 19)
An instructional illustration showing the preparation of an injection. It depicts a hand holding a syringe with a protective cap being removed by pulling it straight off, with a 'CLICK!' sound effect indicated for confirmation.*
Figure (Invega 20)
An instructional illustration showing the proper disposal method for a syringe and vial. The top half depicts a hand placing a syringe into a sharps container marked with a biohazard symbol. The bottom half shows a hand placing a vial into the same sharps container, emphasizing safe disposal of injection-related materials.*
Figure (Invega 21)
A warning text panel stating that thin wall safety needles are specifically designed for use with INVEGA TRINZA injection. It advises that unused needles should be discarded and not saved for future use.*
Chemical Structure (Invega 22)
Chemical structure of paliperidone palmitate, the active ingredient in INVEGA TRINZA extended-release intramuscular injection suspension.*
Figure 1 (Invega 23)
A pharmacokinetic chart showing the effect of other drugs on INVEGA TRINZA (paliperidone palmitate) extended-release intramuscular injection. It displays fold changes and 90% confidence intervals in AUC and Cmax for co-administration with CYP2D6 inhibitor Paroxetine, CYP3A4 inducer Carbamazepine, and Divalproex Sodium ER relative to the reference without interacting drugs.*
Figure 2 (Invega 24)
A pharmacokinetic chart showing the effect of INVEGA TRINZA on Divalproex Sodium ER. The graph plots fold change and 90% confidence intervals for AUC and Cmax, with values around 1.0 indicating no significant interaction or change relative to a reference without interacting drug.*
Figure 3 (Invega 25)
A pharmacokinetic chart illustrating the effect of intrinsic factors on INVEGA TRINZA (paliperidone palmitate) showing fold changes and 90% confidence intervals relative to reference values. The chart compares exposure (AUC) and peak concentration (Cmax) metrics for renal impairment (mild, moderate, severe), hepatic impairment (moderate), and age groups (18-64 versus over 65 years).*
Figure 4 (Invega 26)
A Kaplan-Meier survival curve comparing estimated percentage of subjects with relapse over time (days since randomization) for INVEGA TRINZA injection versus placebo. The plot shows two lines: a dashed line for INVEGA TRINZA and a solid line for placebo, indicating relapse rates tracked up to approximately 420 days.*
Principal Display Panel (273 mg Syringe Carton)
INVEGA TRINZA 273 mg/0.88 mL extended-release injectable suspension (paliperidone palmitate) in a single-dose prefilled syringe carton. The label indicates intramuscular injection, administration every 3 months, and instructions to shake syringe vigorously for at least 15 seconds. The product is from Janssen Pharmaceuticals, Inc. and includes storage instructions and usage cautions.*
Principal Display Panel (410 mg Syringe Carton)
INVEGA TRINZA 410 mg/1.32 mL extended-release injectable suspension for intramuscular injection by Janssen Pharmaceuticals, in a single-dose prefilled syringe. The label emphasizes administering every 3 months and shaking the syringe vigorously for at least 15 seconds before use. It includes storage information and a barcode on the packaging.*
Principal Display Panel (546 mg Syringe Carton)
Packaging label for INVEGA TRINZA 546 mg/1.75 mL extended-release injectable suspension containing paliperidone palmitate. This single-dose prefilled syringe is for intramuscular injection only and is manufactured by Janssen Pharmaceuticals, Inc. The label emphasizes administration every 3 months and instructs to shake the syringe vigorously for at least 15 seconds before use.*
Principal Display Panel (819 mg Syringe Carton)
INVEGA TRINZA 819 mg/2.63 mL extended-release injectable suspension carton for intramuscular injection by Janssen Pharmaceuticals, Inc. The label highlights a single-dose prefilled syringe containing 819 mg paliperidone palmitate in 2.63 mL, with instructions to shake vigorously for 15 seconds and administer every 3 months. Storage instructions specify room temperature 20°C to 25°C (68°F to 77°F) with permitted excursions.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
